Osivax and GC Biopharma unveiled a major partnership focused on developing a more advanced influenza vaccine. The vaccine will combine OVX836 and GC FLU. Osivax secured rights to advance a combo shot.
Older adults face four vaccine decisions this fall, while the national vaccine schedule continues to carry a 2025 date. Flu and pneumonia deaths have declined for 25 years, but one American age group recorded a rise.